Tarveda Therapeutics, Inc.

Abraxis Bioscience, LLC

Placon Therapeutics, Inc.

Tva (abc), LLC

Rajesh R Shinde

Mark T Bilodeau

Richard Wooster

Rossitza Gueorguieva Alargova

Sudhakar Kadiyala

Patrick Lim Soo

Craig Antony Dunbar

Beata Sweryda-Krawiec

Brian H White

Patrick Rosaire Bazinet

Benoît Moreau

Willard Foss

Edward R Lee

Kerry Whalen

Timothy E Barder

Leila Alland

Samantha Perino

Danielle N Rockwood

Danille N Rockwood

Mary Simcox

Christopher Sears

Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.

HSP90 targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Targeted conjugates and particles and formulations thereof

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

HSP90-targeting conjugates and formulations thereof

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

SSTR-targeted conjugates and particles and formulations thereof

Provided herein are use of polymeric excipients, specifically polyvinyl alcohols, optionally in conjunction with sugars, as cryoprotectants to prevent aggregation of PEG-containing particles. Also provided are PEG-containing particles comprising such polymeric excipients.

Use of polymeric excipients for lyophilization or freezing of particles

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.

Compounds, compositions, and methods for the treatment of cancers

Growing community of inventors

Lexington, MA, United States of America

Rajesh R Shinde